Lesson
Definition, Diagnosis, and Etiotypes
COPD is a heterogeneous condition with chronic respiratory symptoms caused by airway and or alveolar abnormalities that produce persistent, often progressive airflow obstruction.
- Clinical context
- Post-bronchodilator spirometry
- Airway and alveolar pathology
- Life-course etiotypes
- Pre-COPD and PRISm
Dyspnea, cough, sputum, infection, and lifetime lung injury
FEV1 divided by FVC below 0.70 with quality review
Airway, emphysema, development, genetics, and environment
Require context and spirometry
Consider COPD with persistent dyspnea, activity limitation, cough, sputum, recurrent lower respiratory infection, or exacerbations plus tobacco, biomass, occupational, pollution, developmental, genetic, or other risk. Confirm with post-bronchodilator FEV1 divided by FVC below 0.70. Pre-bronchodilator testing can help exclude obstruction, but it does not replace post-bronchodilator confirmation.
Interpret the ratio carefully
A fixed ratio improves consistency but can overdiagnose some older adults and underdiagnose some younger adults. Repeat a post-bronchodilator ratio near the threshold, verify effort and quality, compare the clinical pattern, and consider lower-limit-of-normal interpretation when discordance matters. Reversibility magnitude does not reliably separate COPD from asthma.
Connect structure to physiology
Small-airway inflammation, mucus, fibrosis, loss of alveolar attachments, emphysematous destruction, gas trapping, hyperinflation, vascular change, and impaired gas exchange contribute differently across patients. FEV1 captures obstruction but not the full burden of hyperinflation, diffusion loss, exercise limitation, or symptoms.
Use a life-course model
Tobacco remains important, but COPD can arise from biomass and occupational exposure, air pollution, alpha-1 antitrypsin deficiency, infection, impaired lung development, prematurity, tuberculosis, asthma, and accelerated aging. Pre-COPD describes symptoms or structural or functional abnormality without obstruction. PRISm describes reduced FEV1 with a preserved ratio. Neither should be mislabeled established COPD without post-bronchodilator obstruction.
Quick check
Lesson
Severity, Symptoms, Exacerbations, and Multimorbidity
Airflow grade, symptom burden, exacerbation risk, disease activity, gas exchange, imaging, function, and comorbidity describe different dimensions of COPD.
- GOLD airflow grade
- mMRC and CAAT
- ABE assessment
- Disease activity
- Multimorbidity
Obstruction, hyperinflation, diffusion, gas exchange, and exercise
Breathlessness, activity, cough, sleep, energy, and daily impact
One moderate or severe event now activates Group E
Keep spirometry and lived burden separate
Grade airflow obstruction from post-bronchodilator FEV1 percent predicted, then measure symptoms with mMRC and the COPD Assessment Test, now called CAAT in GOLD materials. Severe obstruction can coexist with modest reported symptoms, while major dyspnea can reflect hyperinflation, deconditioning, cardiac disease, anemia, obesity, anxiety, or another process.
Apply the 2026 ABE threshold
Treatment-naive Group A has lower symptoms and no moderate or severe exacerbation in the prior year. Group B has greater symptoms and no moderate or severe exacerbation. Group E includes at least one moderate or severe exacerbation in the prior year, regardless of symptom score. This 2026 threshold reflects the risk carried by even one treated event.
Describe activity and trajectory
Track symptoms, rescue use, lung function, moderate and severe exacerbations, admissions, activity, weight, oxygenation, and treatment response over time. A quiet interval after a recent attack does not erase active risk. A moderate exacerbation generally requires systemic corticosteroid and or antibiotic treatment, while a severe event requires emergency or inpatient care.
Actively seek multimorbidity
Evaluate cardiovascular disease, lung cancer eligibility, bronchiectasis, anxiety and depression, osteoporosis, sarcopenia, malnutrition, obesity, sleep apnea, reflux, diabetes, anemia, frailty, and medication burden. Treat these conditions by their usual standards. Cardioselective beta blockers should not be withheld when a cardiovascular indication exists.
Quick check
Lesson
Bronchodilators, Anti-Inflammatory Drugs, and Devices
Long-acting bronchodilation is the treatment core. Anti-inflammatory benefit depends on phenotype, exacerbation history, molecule, route, and toxicity.
- Beta2 agonists
- Muscarinic antagonists
- ICS benefit and harm
- PDE inhibition
- Device matching
LABA relaxes airway smooth muscle through adrenergic signaling
LAMA reduces cholinergic bronchoconstrictor tone
ICS, PDE inhibition, macrolide, or biologic with safety review
Relax airway smooth muscle through two pathways
Beta2 agonists increase cyclic AMP, while muscarinic antagonists block acetylcholine-driven M3 bronchoconstriction. LABA and LAMA combinations improve bronchodilation through complementary mechanisms. Short-acting bronchodilators remain rescue options, but regular long-acting treatment better supports persistent symptoms.
Use ICS for exacerbation biology, not isolated dyspnea
ICS benefit rises with exacerbation history and higher blood eosinophils. Triple LABA-LAMA-ICS therapy is preferred over LABA-ICS when an ICS is indicated. Consider pneumonia, oral candidiasis, dysphonia, skin bruising, bone, metabolic, eye, mycobacterial, and systemic exposure risks. Asthma features create a separate need to follow asthma ICS principles.
Know the phosphodiesterase options
Roflumilast is an oral selective PDE4 inhibitor used to reduce exacerbation risk in selected patients with severe obstruction, chronic bronchitis, and recurrent attacks, especially after hospitalization. It is not a bronchodilator. Monitor diarrhea, weight loss, sleep, mood, and suicidality. Ensifentrine inhibits PDE3 and PDE4 and is FDA-labeled as twice-daily nebulized adult maintenance therapy. It is not rescue treatment and requires psychiatric, hepatic, paradoxical-bronchospasm, and device counseling.
Treat the device as part of the prescription
Metered-dose, dry-powder, soft-mist, and nebulized systems differ in inspiratory flow, coordination, dexterity, preparation, cleaning, portability, and cost. Observe inhalation, check the dose counter and supply, and simplify when possible. A nebulizer can help selected patients but is not inherently more effective when a handheld device is used correctly.
Quick check
Lesson
Initial and Follow-Up Pharmacologic Strategy
Initial treatment uses ABE classification. Follow-up treatment starts from the current regimen and follows the dominant treatable trait: persistent dyspnea or exacerbations.
- Initial ABE therapy
- Dyspnea pathway
- Exacerbation pathway
- ICS and eosinophils
- Advanced add-on treatment
Bronchodilator for A, LABA-LAMA for most B and E
Then audit device, diagnosis, rehabilitation, and comorbidity
Use events, eosinophils, infection risk, and current regimen
Start from A, B, or E only when treatment naive
Group A receives a bronchodilator selected for symptom relief, with a long-acting option preferred except for very occasional breathlessness. Group B generally begins LABA-LAMA. Group E generally begins LABA-LAMA, with initial triple therapy considered when eosinophils are at least 300 cells per microliter. LABA-ICS is not encouraged as the routine COPD combination.
Follow the dominant unresolved trait
For dyspnea on one long-acting bronchodilator, escalate to LABA-LAMA. If dyspnea persists on dual therapy, verify the diagnosis, inhaler, adherence, comorbidity, rehabilitation, and device or molecule choice. Ensifentrine may be considered as add-on maintenance treatment in an appropriate adult. Do not add ICS solely for breathlessness without exacerbation biology.
Use eosinophils as a probability marker
For exacerbations on a single long-acting bronchodilator, LABA-LAMA is appropriate when eosinophils are below 300, while triple therapy becomes more likely to help as eosinophils rise. On LABA-LAMA, consider triple therapy when eosinophils are at least 100. The expected ICS effect is strongest at higher counts and low below 100, but decisions still include attack history, infection and pneumonia risk, and asthma.
Escalate beyond triple therapy selectively
Persistent exacerbations can trigger evaluation for roflumilast in chronic bronchitis with FEV1 below 50 percent, azithromycin particularly in former smokers after QT, hearing, resistance, and interaction review, or phenotype-directed biologic therapy under current labeling. Dupilumab and mepolizumab now have US COPD indications for selected eosinophilic disease. Reassess benefit, adverse effects, adherence, and continued eligibility rather than leaving advanced treatment unexamined.
Quick check
Lesson
Risk Reduction, Rehabilitation, Oxygen, and Advanced Care
COPD care changes exposure, infection risk, physical capacity, nutrition, oxygenation, ventilation, and goals in addition to prescribing inhalers.
- Tobacco treatment
- Vaccination
- Pulmonary rehabilitation
- Long-term oxygen
- Ventilation and interventions
Tobacco treatment, clean air, and current vaccination
Exercise, education, self-management, nutrition, and psychosocial care
Use physiologic criteria, reassessment, and patient-centered goals
Remove the injurious exposure
Ask about cigarettes, vaping, cannabis, biomass, occupational dust and fumes, and household or outdoor pollution. Offer behavioral support plus evidence-based tobacco pharmacotherapy. Document readiness, triggers, prior attempts, withdrawal, contraindications, and follow-up. E-cigarettes should not be presented as an established safe cessation treatment.
Prevent infection and restore capacity
Use current local recommendations for influenza, pneumococcal, COVID-19, RSV, Tdap, and zoster vaccination. Pulmonary rehabilitation combines individualized exercise, disease education, self-management, breathing strategies, and nutritional or psychosocial support. It improves exercise capacity, symptoms, and quality of life and is especially important after hospitalization.
Prescribe oxygen for the right physiology
Long-term oxygen improves survival in severe chronic resting hypoxemia, generally PaO2 at or below 55 mmHg or below 60 mmHg with cor pulmonale or secondary polycythemia. Confirm stability and reassess after an acute illness. Do not routinely prescribe long-term oxygen for stable moderate resting or exercise-only desaturation without another qualifying rationale.
Escalate support around patient goals
Selected patients with persistent daytime hypercapnia after hospitalization may benefit from long-term noninvasive ventilation. Advanced emphysema may prompt lung-volume reduction, endobronchial, bullectomy, or transplant evaluation after optimized care and phenotype imaging. Palliative treatment, advance care planning, and hospice can coexist with disease-directed therapy.
Quick check
Lesson
Acute Exacerbations, Respiratory Failure, and Recovery
A COPD exacerbation worsens dyspnea and or cough and sputum over days, but pneumonia, pulmonary embolism, heart failure, pneumothorax, arrhythmia, and other emergencies can present similarly.
- Definition and mimics
- Acute bronchodilation
- Steroids and antibiotics
- Oxygen and ventilation
- Discharge prevention
Infection, pollution, pneumonia, embolism, heart failure, or pneumothorax
SABA, selected SAMA, controlled oxygen, steroid, antibiotic, and NIV
Maintenance therapy, technique, rehabilitation, action plan, and follow-up
Diagnose the event and its competitors
An exacerbation develops over up to about 14 days with worsening dyspnea and or cough and sputum, often with tachypnea or tachycardia. Assess oxygenation, ventilation, mental status, work of breathing, hemodynamics, imaging, ECG, infection, and thrombotic risk. Pneumonia, pulmonary embolism, acute heart failure, pneumothorax, acute coronary disease, and arrhythmia can mimic or worsen the event.
Reverse airflow limitation promptly
Use repeated SABA with or without a short-acting muscarinic antagonist for moderate or severe exacerbations and restart or initiate long-acting maintenance bronchodilation early. Avoid methylxanthines because toxicity outweighs benefit. Delivery can use a metered-dose inhaler with spacer or nebulizer according to severity and ability.
Target inflammation and likely bacterial disease
Use systemic corticosteroid for up to five days in moderate or severe exacerbations, commonly prednisone-equivalent 40 mg daily when appropriate. Use a five-day antibiotic course when purulent sputum, bacterial evidence, ventilatory support, prior infection pattern, or other clinical criteria support benefit. Choose around local resistance, cultures, allergies, QT risk, renal function, and prior organisms.
Support gas exchange and prevent recurrence
Titrate oxygen, commonly to 88 to 92 percent while blood gases clarify carbon dioxide retention. Noninvasive ventilation is preferred for eligible acute hypercapnic respiratory failure because it reduces intubation and mortality. Before discharge, reconcile inhalers, consider triple therapy when attacks and eosinophils support it, confirm technique and access, arrange rehabilitation and early follow-up, update vaccinations and action planning, and reassess oxygen need after recovery.
Quick check
Module test
Check the connections.
Each attempt draws 10 questions from the complete 100 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.